Vivesto AB (VIVE.ST)
SEK 0.27
(-1.45%)
SEK 0.27
(-1.45%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2022 | -0.74 SEK | -138.71% |
| 2021 | -0.31 SEK | -1271.68% |
| 2020 | -0.02 SEK | 14.39% |
| 2019 | -0.03 SEK | 95.45% |
| 2018 | -0.58 SEK | -23.4% |
| 2017 | -0.47 SEK | 47.19% |
| 2016 | -0.89 SEK | 3.26% |
| 2015 | -0.92 SEK | -15.0% |
| 2014 | -0.80 SEK | -1.27% |
| 2013 | -0.79 SEK | -21.54% |
| 2012 | -0.65 SEK | 10.96% |
| 2011 | -0.73 SEK | 19.78% |
| 2010 | -0.91 SEK | -225.0% |
| 2009 | -0.28 SEK | -115.38% |
| 2008 | -0.13 SEK | -40.39% |
| 2007 | -0.09 SEK | 51.26% |
| 2006 | -0.19 SEK | -35.71% |
| 2005 | -0.14 SEK | -390.46% |
| 2004 | 0.05 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 Q1 | -0.04 SEK | 91.91% |
| 2023 Q2 | -0.05 SEK | -53.09% |
| 2022 Q3 | -0.14 SEK | -79.49% |
| 2022 FY | - SEK | -138.71% |
| 2022 Q1 | -0.05 SEK | -785.0% |
| 2022 Q2 | -0.08 SEK | -46.89% |
| 2022 Q4 | -0.44 SEK | -214.29% |
| 2021 Q1 | -0.09 SEK | 81.43% |
| 2021 Q4 | -0.01 SEK | 91.32% |
| 2021 Q2 | -0.12 SEK | -31.87% |
| 2021 Q3 | -0.07 SEK | 42.42% |
| 2021 FY | - SEK | -1271.68% |
| 2020 Q1 | 0.24 SEK | 250.0% |
| 2020 Q2 | -0.12 SEK | -150.0% |
| 2020 Q3 | -0.12 SEK | 0.0% |
| 2020 Q4 | -0.49 SEK | -308.33% |
| 2020 FY | - SEK | 14.39% |
| 2019 Q1 | -0.15 SEK | -50.0% |
| 2019 Q4 | -0.16 SEK | -182.69% |
| 2019 FY | - SEK | 95.45% |
| 2019 Q3 | -0.06 SEK | 56.46% |
| 2019 Q2 | -0.13 SEK | 13.33% |
| 2018 Q2 | -0.12 SEK | 0.0% |
| 2018 FY | - SEK | -23.4% |
| 2018 Q4 | -0.10 SEK | 54.55% |
| 2018 Q1 | -0.12 SEK | -9.09% |
| 2018 Q3 | -0.22 SEK | -83.33% |
| 2017 Q2 | -0.15 SEK | 31.82% |
| 2017 Q4 | -0.11 SEK | -16.9% |
| 2017 FY | - SEK | 47.19% |
| 2017 Q3 | -0.09 SEK | 37.27% |
| 2017 Q1 | -0.22 SEK | 0.0% |
| 2016 FY | - SEK | 3.26% |
| 2016 Q1 | -0.19 SEK | -26.67% |
| 2016 Q4 | -0.22 SEK | 12.0% |
| 2016 Q3 | -0.25 SEK | -13.64% |
| 2016 Q2 | -0.22 SEK | -15.79% |
| 2015 Q1 | -0.19 SEK | 0.0% |
| 2015 Q4 | -0.15 SEK | 46.43% |
| 2015 Q2 | -0.25 SEK | -31.58% |
| 2015 Q3 | -0.28 SEK | -12.0% |
| 2015 FY | - SEK | -15.0% |
| 2014 Q2 | -0.23 SEK | 14.81% |
| 2014 Q3 | -0.19 SEK | 17.39% |
| 2014 Q4 | -0.19 SEK | 0.0% |
| 2014 Q1 | -0.27 SEK | -17.39% |
| 2014 FY | - SEK | -1.27% |
| 2013 Q4 | -0.23 SEK | -64.29% |
| 2013 Q3 | -0.14 SEK | 0.0% |
| 2013 Q2 | -0.14 SEK | 17.65% |
| 2013 Q1 | -0.17 SEK | -30.77% |
| 2013 FY | - SEK | -21.54% |
| 2012 Q3 | -0.15 SEK | 28.57% |
| 2012 Q4 | -0.13 SEK | 13.33% |
| 2012 FY | - SEK | 10.96% |
| 2012 Q1 | -0.21 SEK | -16.67% |
| 2012 Q2 | -0.21 SEK | 0.0% |
| 2011 Q4 | -0.18 SEK | -934.48% |
| 2011 FY | - SEK | 19.78% |
| 2011 Q1 | -0.25 SEK | -25.0% |
| 2011 Q2 | -0.18 SEK | 28.0% |
| 2011 Q3 | -0.02 SEK | 90.33% |
| 2010 Q2 | -0.19 SEK | -122.48% |
| 2010 Q3 | -0.27 SEK | -42.11% |
| 2010 Q4 | -0.20 SEK | 25.93% |
| 2010 FY | - SEK | -225.0% |
| 2010 Q1 | -0.09 SEK | 55.05% |
| 2009 Q4 | -0.19 SEK | -18.75% |
| 2009 Q2 | 0.17 SEK | 0.0% |
| 2009 Q3 | -0.16 SEK | -194.12% |
| 2009 FY | - SEK | -115.38% |
| 2008 FY | - SEK | -40.39% |
| 2007 FY | - SEK | 51.26% |
| 2006 FY | - SEK | -35.71% |
| 2005 FY | - SEK | -390.46% |
| 2004 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AcuCort AB | -0.16 SEK | -362.5% |
| AlzeCure Pharma AB (publ) | -0.60 SEK | -23.333% |
| BioGaia AB (publ) | 3.62 SEK | 120.442% |
| Enzymatica AB (publ) | -0.28 SEK | -164.286% |
| Enorama Pharma AB (publ) | -1.61 SEK | 54.037% |
| Gabather AB (publ) | -0.65 SEK | -13.846% |
| Klaria Pharma Holding AB (publ.) | -0.36 SEK | -105.556% |
| Moberg Pharma AB (publ) | -1.33 SEK | 44.361% |
| Nanexa AB (publ) | -1.09 SEK | 32.11% |
| Newbury Pharmaceuticals AB (publ) | -0.72 SEK | -2.778% |
| ODI Pharma AB | 0.02 SEK | 3262.393% |
| Orexo AB (publ) | -3.73 SEK | 80.161% |
| Probi AB (publ) | 1.48 SEK | 150.0% |
| Swedencare AB (publ) | 0.37 SEK | 300.0% |
| Swedish Orphan Biovitrum AB (publ) | 7.47 SEK | 109.906% |
| Toleranzia AB | -0.06 SEK | -1221.429% |